Corbus starts TEMPO-1 as Corbus Pharmaceuticals stock sits 71.89 percent below its high

Published on 10/07/2026 at 02:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TEMPO-1 will test CRB-701 in 250 patients against three treatments. Corbus Pharmaceuticals stock sits 71.89 percent below its high.

CRBP, US21833P3010, Illustration mit AI erstellt.

Corbus Pharmaceuticals stock sat 71.89 percent below its USD 20.56 52-week high on October 6, 2026, as the company advanced its lead oncology program. According to Corbus Pharmaceuticals on September 29, 2026, the first patient was dosed in the registrational TEMPO-1 study of CRB-701.

TEMPO-1 enrolls 250 patients

The randomized controlled study is designed to enroll 250 patients with second-line and later oropharyngeal squamous cell carcinoma. CRB-701 will be compared with investigator choice of capecitabine, cetuximab or docetaxel, while objective response rate is intended to support a potential accelerated approval.

The company said the study follows Phase 1/2 data presented at the 2026 American Society of Clinical Oncology Annual Meeting. In the 3.6 milligrams per kilogram dose group, CRB-701 produced a confirmed objective response rate of 42.90 percent, a median duration of response of 6.30 months and median progression-free survival of 5.60 months, according to Corbus Pharmaceuticals.

Losses sharpen the funding question

Corbus reported diluted earnings per share of USD -1.81 for the second quarter of 2026, compared with a consensus estimate of USD -1.26, a shortfall of USD 0.55, according to MarketBeat on August 6, 2026. Structured financial data put second-quarter net loss at USD 35.0 million, cash at USD 23.4 million and operating cash flow at negative USD 29.6 million for the same period.

The figures explain why TEMPO-1 is more than a clinical milestone. The trial must convert early response data into controlled evidence while Corbus manages a cash balance that was below its second-quarter operating outflow.

CRBP remains far below its yearly high

CRBP had a market capitalization of USD 107.1 million on October 6, 2026, with a 52-week range of USD 5.65 to USD 20.56. The latest structured quote was USD 5.78 at 4:00 p.m. ET on October 6, 2026, placing the stock USD 14.78 below its yearly high and making the clinical readout path central to valuation.

Lang & Schwarz showed a prior close of EUR 5.13 for October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Corbus Pharmaceuticals stock.